Physiologic Regulation of EPO Production for CKD-Anemia: An Opportunity to Enhance Access to Care
Released On
December 21, 2022
Expires On
December 21, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
The primary target audiences for this activity are Nephrologists, Dialysis Center Medical Directors, Hospitalists, Hematologists, and Specialty NPs and PAs. Secondary audiences include Primary Care Clinicians, Internal Medicine Specialists, Cardiologists, Endocrinologists, Family Medicine and/or Allied NPs and PAs.
Topic(s)
Kidney Disease, Chronic Kidney Disease, CKD, Anemia, Anemia in CKD, Iron Deficiency, Erythropoietin, EPO, Iron supplementation, Erythropoiesis-stimulating agents, Hypoxia, Hypoxia-inducible factor prolyl hydroxylase inhibitors, HIF-PHIs, KDIGO guidelines, Hepcidin, Dialysis, End stage kidney disease, ESKD
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.
in collaboration with the Kidney Disease: Impacting Global Outcomes (KDIGO).
This educational activity is supported by an educational grant from GSK.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
The educational design of this activity addresses the needs of nephrologists, dialysis center medical directors, hospitalists, hematologists, and specialty NPs and PAs. Secondary audiences include primary care clinicians, internal medicine specialists, cardiologists, endocrinologists, family medicine and/or allied NPs and PAs.
Statement of Need/Program Overview
Anemia in chronic kidney disease (CKD) is often under-recognized and undertreated, leaving patients to live with a significant health burden. Further, patients from certain racial and ethnic groups disproportionately suffer from poor screening rates and a lack of appropriate management of their anemia. Emerging agents for the management of anemia in CKD target a novel physiologic pathway and, if approved, could provide additional options to relieve the burden associated with anemia in CKD.
Join a panel of expert nephrologists and patient advocates to explore the current treatment landscape for anemia in CKD, including iron supplementation and use of erythropoiesis-stimulating agents. Panelists will review emerging agents, investigational hypoxia-inducible factor prolyl hydroxylase inhibitors, including their mechanism of action, efficacy, and safety. Clinicians will also discover strategies to improve access to anemia care for under-resourced and diverse patient populations.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the personal and societal burden of anemia and its care on patients with CKD, including those undergoing dialysis
- Discuss strategies to enhance access to anemia care for racial groups, such as Black patients, to ensure they receive proper and timely diagnoses and management
- Summarize the role of hypoxia-inducible factor in the production of EPO
- Summarize experience data with hypoxia-inducible factor prolyl hydroxylase inhibitors in increasing Hb levels compared to standard of care in both dialysis-dependent patients and patients not receiving dialysis
Faculty
Lynda Szczech, MD, MSCE
Nephrologist
David C. Wheeler, MD
Professor of Kidney Medicine
University College London
Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
University of Maryland School of Medicine
Joint Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
|---|---|
| Lynda Szczech, MD, MSCE Nephrologist |
Consulting Fee (e.g., Advisory Board): CeleCor Stock Shareholder: FibroGen |
| David C. Wheeler, MD Professor of Kidney Medicine University College London |
Consulting Fee (e.g., Advisory Board): Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Tricida Contracted Research: AstraZeneca Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Mundipharma, Tricida, Vifor, Zydus Speakers' Bureau: Amgen, Astellas, AstraZeneca |
| Matthew R. Weir, MD Professor and Chief Division of Nephrology University of Maryland School of Medicine |
Consulting Fee (e.g., Advisory Board): Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Glaxo, Janssen, NovoNordisk, Vifor |
The planners and managers have the following relevant financial relationships with ineligible companies:
| Name of Planner or Manager | Reported Financial Relationship |
|---|---|
| Lindsay Borvansky | Nothing to disclose |
| Andrea Funk | Nothing to disclose |
| Liddy Knight | Nothing to disclose |
| Ashley Cann | Nothing to disclose |
| Lauren Sinclair | Nothing to disclose |
| Jaimee Harris-Gold | Nothing to disclose |
| Terry Glauser | Nothing to disclose |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in this activity. To participate in the activity, go to XXX or XXX. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For Pharmacists: Upon receipt of the completed activity evaluation form credit will be submitted to the NABP CPE Monitor Service. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com
PlatformQ Health Privacy Policy:
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/